In study II patients were randomly assigned to receive placebo (229 patients), or rasagiline 1 mg/ day (231 patients) or the catechol-O– methyl transferase (COMT) inhibitor, entacapone, 200 mg taken along with scheduled doses of levodopa (LD)/ decarboxylase inhibitor (227 patients), and were treated for 18 weeks.